• By Andrew Williams

    USPTO Building FacadeToday, March 16, 2014, marks the eighteen-month anniversary of the inter partes review ("IPR") system of challenging issued patents at the Patent Office.  We thought that this would be an appropriate time to look back at the last year and a half and reflect on the system thus far.  In that time, the Office has seen close to 1,000 petitions filed.  Looking back only six months ago, no final decisions had issued by the one-year anniversary.  But to date, more than 20 final written decisions have been issued by the Patent Trial and Appeal Board ("PTAB" or "Board").  This number will should increase at even a faster rate, considering petition filings have only increased since September 16, 2012.  Initially, there was a question whether the Board would essentially "rubber-stamp" the original decisions of the patent examiners, or whether this system would be a viable alternative to tackle the perceived patent-troll problem.  There remains little doubt today which way the Board is leaning — the overwhelming majority of cases have seen all of the reviewed claims canceled.  Of the questions that remain, some of the more interesting include why the challengers have been so successful, whether this trend of claim cancellation will continue, and what will the Federal Circuit do when it starts hearing appeals from all of these proceedings.

    The first decision rendered set the tone for most that followed.  As we reported at the time, the first inter partes review opinion was released last November in a case related to speed limit indicators on GPS devices.  The outcome of IPR2012-00001 (Garmin USA, Inc. (Petitioner) v. Cuozzo Speed Technologies LLC (Patent Owner)) was considered good news for parties wishing to challenge the validity of patents at the Office.  Since that time, of the more than twenty Final Written Decisions based on the merits of the case, the large majority went against the patent holder.  In fact, it was not until February 19, 2014 that the PTAB upheld any claim that it had reviewed.  On that date, the Court issued two such decisions.  The first, Microsoft Corp. (Petitioner) v. Proxyconn, Inc. (Patent Owner) (IPR2012-00026 and IPR2013-00109), involved U.S. Patent No. 6,757,717, which was directed to systems for data access in a packet switched network.  Microsoft was able to show that all reviewed claims except claim 24 were either anticipated or obvious in view of the prior art.  Nevertheless, because it was unable to establish by a preponderance of the evidence that the final claim was unpatentable, that claim was spared.  On the same day, in Synopsys, Inc. (Petitioner) v. Mentor Graphics Corp. (Patent Owner) (IPR2012-00042), the Board upheld the validity of several claims in a patent related to the fields of simulation and prototyping of integrated circuits.  Even with these few successes by the patent holders, it is interesting that the requestors have been so successful in cancelling all of the reviewed claims of the patent at issue.

    Of course, this raises the issue of whether the PTAB is predisposed to "correct" any perceived mistakes previously made by the Patent Office, or whether the Office has just issued that many flawed patents.  On the one hand, it is possible that the PTAB is cancelling so many claims because it is mainly reviewing patents that qualify as the worst of the worst.  After all, filing a petition is not cheap, so it would stand to reason that a party would only file one if they believed they had a reasonable chance at success.  The counter to this argument is that most petitions are directed to patents that are already involved in litigation.  In such cases, the accused infringer has every incentive to seek relief from the Board (regardless of the actual merits of the case).  Not only is the standard for invalidating the claims lower (preponderance of the evidence versus clear and convincing evidence), but claims are given their broadest reasonable interpretation by the Board, as opposed to the narrower standard used by Federal Courts.  Another reason that the Board may appear predisposed to cancel claims is because it must first determine that there is a reasonable likelihood that the petitioner will prevail before a trial is instituted.  Therefore, when looking at the success rate of petitioners, it is probably more useful to look at the number of cases that make it past this initial hurdle.  We will look at these figures in a future post.

    Nevertheless, there is at least one outspoken critic of the PTAB's actions.  According to a report in the Wall Street Journal, Chief Judge Rader appears to be alarmed by the rate at which claims are being canceled by the Board.  In fact, as reported in that article, he equated the Board's panels with "death squads," at least with regard to intellectual property rights.  He expressed concern that the Board's actions would decrease the incentives necessary for human progress.  These comments might be considered good news for patent holders, because they have the ability to appeal the Board's decision to the Federal Circuit.  In fact, the patent holder in the first decided case, Cuozzo Speed Technologies, has already filed an appeal with the appellate court.  As of March 12, 2014, counsel for Garmin had not yet filed an appearance or any of the other requisite preliminary information with the Federal Circuit.  We will also continue to monitor this case.

    Based on a review of the cases with Final Written Decisions as mentioned above, and the conventional wisdom regarding the IPR system, the majority of patents reviewed have been related to computer technology and the like.  However, on March 6, 2014, the Board issued three Final Decisions in cases involving Illumina as the petitioner and the Trustees of Columbia University in the City of New York as the patent holder.  These cases involved patents related to "sequencing DNA by synthesis" or "SBS."  In all three reviews (IPR2012-00006, IPR2012-00007, and IPR2013-00011), the Board invalidated all of the reviewed claims as obvious in view of the prior art.  We will report on those three cases in more detail in a future post.  Moreover, there have been a significant number of petitions filed related to the biotech and pharmaceutical industry, and we can only expect this number to increase in the coming months.

    It is interesting looking back at the trends at the Board in the past 18 months.  However, considering that IPRs are to be concluded within a 12-to-18-month period, we should continue to see a lot more decisions rendered by the two-year anniversary next September.  A review at that time should help clarify whether the current trends are based on a sample size that is too small, or whether they will be the status quo for the foreseeable future.

  • CalendarMarch 20, 2014 – "Parallel Patent Proceedings Before the PTAB and Federal Court Post-AIA — Navigating Litigation Stays, Discovery and Settlements Concurrent with PTAB Review" (Strafford) – 1:00 to 2:30 pm (EST)

    March 20, 2014 – "New USPTO Examination Guidelines for Myriad and Mayo" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    March 24-26, 2014 – Medical Device Patents*** (American Conference Institute) – Chicago, IL

    March 25, 2014 – 24th Annual Conference on USPTO Law and Practice (PTO Day) (Intellectual Property Owners Association and U.S. Patent and Trademark Office) – Washington, DC

    March 25, 2014 – "Big Data Litigation in an Era of Big Data Privacy Concerns: Recent Developments in International Data Privacy Law and Their Impact on U.S. Litigation" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    March 26, 2014 – "Trade Secret vs. Patent Protection After AIA: Making the Choice — Understanding AIA's Impact on Trade Secrets, Evaluating the Protection Options, Weighing the Benefits and Risks" (Strafford) – 1:00 to 2:30 pm (EDT)

    March 26-27, 2014 – Biotech Patenting*** (C5) – Munich, Germany

    March 31 to April 2, 2014 - Life Sciences Collaborative Agreements and Acquisitions*** (American Conference Institute) - New York, NY

    April 23, 2014 – European biotech patent law update (D Young & Co) – 4:00 am, 7:00 am, and 12:00 pm (ET)

    April 23-25, 2014 – 2014 Spring Intellectual Property Counsels Committee (IPCC) Conference (Biotechnology Industry Organization) – Palm Springs, CA

    April 28-29, 2014 – Paragraph IV Disputes*** (American Conference Institute) – New York, NY

    August 13-15, 2014 – Advanced Patent Law Seminars (Chisum Patent Academy) - Seattle, WA

    August 18-20, 2014 – Advanced Patent Law Seminars (Chisum Patent Academy) - Seattle, WA

    ***Patent Docs is a media partner of this conference or CLE

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar on the "New USPTO Examination Guidelines for Myriad and Mayo" on March 20, 2014 beginning at 2:00 pm (ET).  A panel consisting of Courtenay Brinckerhoff of Foley & Lardner; Duane Marks of Roche; and Raul Tamayo, senior legal advisor in the U.S. Patent and Trademark Office's Office of Patent Legal Administration (OPLA) will discuss the impact of the USPTO's Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural Products on the patenting of drugs and of diagnostic methods, and consider how the guidelines will work in practice.

    The registration fee for the webinar is $130 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • By Michael Borella and Andrew Williams

    EconomistOn March 8th, The Economist published an article deriding both so-called "patent trolls" and "software patents" as being impediments to innovation in the United States.  Unfortunately, as we have seen all too often when the mainstream media discusses the patent system, the article contains unsupported assertions, draws questionable conclusions, and displays a profoundly flawed understanding of patent law.  Such commentary is particularly troublesome in this case because of the wide circulation of this periodical.

    At the outset, the article contains a proclamation that the United States' patent system is "dysfunctional," suggesting this fact is a forgone conclusion to the uninformed reader.  Nevertheless, in explaining how the reported developments are meant to "solve" this supposed crisis, the author reveals his unfamiliarity with the philosophical basis of the patent system in this country.  For example, the article equates non-practicing entities ("NPE") with "trolls."  The term "NPE," however, encompasses all entities that do not manufacture products, including most universities, research institutions, and individual inventors.  Even the reviled "patent assertion entities" have been acknowledged by most to serve an important role as mediator between such NPEs and operating companies often necessary to commercialize inventions.  In fact, the United States' system purposefully encourages such actions by making patent property rights freely assignable and eschewing a "working" requirement.  This is thought to help make the system accessible to everyone, not just those with abundant resources.

    Certainly, no one is denying that there are actors that abuse the litigation system in this country, both with regard to intellectual property rights and otherwise.  However, elevating this minority of cases to be representative of the norm is simply unproductive.  So is the dissemination of questionable statistics.  For example, the article states as fact that patent "trolls" cost U.S. companies $29 billion in 2011.  It is presumed that the author is referring to the research of James Bessen and Michael J. Meurer, which has come under recent scrutiny because of the particular methodology used.  See, e.g., Schwartz & Kesan, Analyzing the Role of Non-Practicing Entities in the Patent System, Cornell Law Review, Vol. 99:2, pp. 425-56 (2014).  As a result, the implications that can be drawn from the data with regard to the impact of "trolls" on the system are questionable at best.

    Moreover, the article's description of the patentability requirements in the United States also betrays the author's lack of understanding of the topic.  With regard to patentable subject matter, the article uses "boiling water to make tea" as an example of a "common idea" which certainly must be a law of nature, natural phenomenon, or abstract idea.  However, not only is this example not apropos, but it actually supports the counterpoint.  Heating water itself might occur in nature, but the application of that "natural" process to "make tea" does not.  And, even though people were certainly brewing tea before the United States' patent system was formed, does this mean Keurig was undeserving of a patent to its K-cups, which were essentially a new way to make tea?

    Even worse, to support the allegation that the United States is issuing non-novel and obvious patents, the article mentions a single patent directed to "upgrading computer software over the internet."  Noticeably missing, however, was the patent number, title, inventor(s), and date of filing, without which it is impossible to determine just what would qualify as prior art.  The article appears to be referencing U.S Patent No. 5,771,354, which was the subject of a This American Life episode in 2013 ("When Patents Attack . . . Part Two!").  If so, contrary to the suggestion in the article, the invention claimed in that patent dated back to the early 1990s, and was ultimately found to be invalid by a jury not because the invention was being practiced in the prior art, but because the correct inventors were not listed on the patent.

    Nonetheless, the reference to the "computer software upgrade" patent is yet another example of how the media mistakenly characterizes a patented invention in a few short words, rather than by the patent's allowed claims.  While gospel to patent attorneys, the well-established principle that "the claims define the invention" gets little attention elsewhere.  Instead, it is easy for a commentator to read the patent's title, abstract, part of its summary, or a few of its drawings, and then provide an over-simplified synopsis of what the patent allegedly covers.  Such an interpretation is not in accordance with U.S. patent law, where special court hearings are used during litigation for the sole purpose of defining the scope of asserted claims.  Simply put, one cannot determine what a patent actually protects by attempting to determine the "gist" of the invention from the specification — a careful evaluation of the claims is required.

    This type of fundamentally flawed analysis is often directed to software and business method patents.  Never mind that neither type of patent is actually defined by the author, or that many patents purportedly directed to either of these technologies explicitly claim computer hardware or other types of physical devices carrying out, or being impacted by, the steps of a method claim.  Perhaps software in particular is an easy target for such bullying, because it is less tangible than say, a cotton gin or a light bulb, and often operates invisibly.

    However, the implication that software is too abstract to warrant patent protection unfairly singles out one of the greatest drivers of the U.S. economy over the last forty years.  A major aspect of innovation is to make products and services faster, cheaper, and better.  The patent system is intended to incentivize individuals and organizations to publicly disclose such inventions, and as a result receive a limited property right thereover.  Despite contentions of the deleterious impact of a "broken" patent system on the software industry, the computer and information industry as a whole continues to grow, as evidenced by recent record-breaking stock values, billion-dollar acquisitions, and successful initial public offerings.  A broad exclusion of computer-implemented inventions is illogical and disregards the fundamental tradeoff on which the system is based.  A ban on software patents would make as much sense as, for example, barring any invention that uses plastic from being patented.

    To the extent that criticism of the patent system might be warranted, the notion that software and business methods should be unpatentable per se is gross overreaction.  In addition to having to meet the patent-eligibility bar for subject matter, a claimed invention must also be novel, non-obvious, and described in such a way that it can be practiced by one of ordinary skill in the art.  The inventions of Bilski v. Kappos, Mayo v. Prometheus, and Alice v. CLS Bank have only been analyzed for validity under the subject matter rubric.  In these cases, the Supreme Court has applied (or in the case of CLS Bank, is being asked to apply) the blunt knife of subject matter eligibility rather than the more incisive tools of novelty and obviousness.

    As noted by the Court in 1980's Diamond v. Diehr, "[t]he 'novelty' of any element or steps in a process, or even of the process itself, is of no relevance in determining whether the subject matter of a claim falls within [patentable subject matter]."  This understanding was in accordance with that of Judge Giles Rich, coauthor of the 1952 Patent Statute, who wrote "[a]chieving the ultimate goal of a patent [requires] having the separate keys to open in succession the three doors of [patentable subject matter, novelty, and non-obviousness]."

    The Court's recent Mayo decision has been roundly criticized for combining considerations of novelty and obviousness into the patent-eligibility inquiry in a way that requires determining the "gist" of the invention.  Consequently, Mayo runs counter to the statute, the Court's own precedent, and well-established practices of claim interpretation.  And yet, Mayo may be the standard under which CLS Bank is decided.  The problem lies not in the topic of these patents, but in the inherent subjectivity of the Mayo analysis.  The fractured, six-opinion Federal Circuit ruling in CLS Bank demonstrates that ten federal judges, who are experts in patent law, could not agree how Mayo should be applied.

    Surely, not all patent applications that claim software or business methods should be allowed.  Some will be too broad, obvious, or vague.  But this analysis is best carried out on a case-by-case basis by well-educated USPTO examiners who apply workable and reasonably objective standards.

    The article ends with yet another oft-asserted falsehood — that copyright would be a "perfectly adequate means of protecting and rewarding software developers for their ingenuity."  Copyright does not protect inventions — it protects expressions of ideas.  In the case of software, this would be the source or object code itself.  If software innovators were required to rely on the weak protection that copyright provides, the computer industry would become rife with clean-room copyists who misappropriate the ideas behind innovative software by developing cloned applications.  And the so-called "trolls" are supposed to be a drain on the economy?

  • By Donald Zuhn

    USPTO SealIn an interim rule published in the Federal Register last week (79 Fed. Reg. 12386), the U.S. Patent and Trademark Office indicated that the time periods for meeting certain requirements for filing a request for Track I prioritized examination could be expanded while maintaining the Office's ability to timely examine the patent application.  The Office notes that the rules changes are intended to simplify prioritized examination ("Track I") practice by reducing the number of requests that must be dismissed and improving access to prioritized examination.

    The requirements for which the time periods are being expanded are: the submission, upon filing, of an inventor's oath or declaration and all required fees, as well as an application containing no more than four independent claims, thirty total claims, and no multiple dependent claims.  In particular, the rules changes would (1) postpone the requirement to file an inventor's oath or declaration if an application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is present upon filing, (2) provide a non-extendable one-month period (following notification of noncompliance from the Office) to file an amendment to cancel any independent claims in excess of four, any total claims in excess of thirty, or any multiple dependent claim, and (3) no longer require the payment of excess claims fees or the application size fee upon filing.  The notice indicates that the rules changes, which have an effective date of March 5, 2014, apply to applications filed under 35 U.S.C. 111(a) on or after September 16, 2012, in which a first action has not been mailed.

    The Office is seeking comments regarding the interim rule, which must be submitted by May 5, 2014.  Comments can be sent by e-mail to AC93.comments@uspto.gov; by regular mail to Mail Stop Comments — Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313–1450, marked to the attention of John R. Cottingham, Director, Office of Petitions, Office of the Deputy Commissioner for Patent Examination Policy; or by using the Federal eRulemaking Portal.

  • By Kevin E. Noonan

    MyriadIn a 106-page opinion, U.S. District Court Judge Robert J. Shelby on Monday denied Myriad Genetics motion for preliminary injunction in Myriad Genetics v. Ambry Genetics.  Characteristic of its aggressive defense of its patent rights, the motion was, as the District Court noted, for "extraordinary" relief and thus not routine nor was the Court expected to grant the motion.  The Court's detailed explication of the history of the Myriad case and the contentions of the parties will be set forth in a later post.  This post is concerned with the outcome, and the grounds that the District Court relied upon in denying the motion.

    The standards for a preliminary injunction are four:  the patentee has to establish a likelihood of success on the merits, that she will be irreparably harmed should the injunction not issue, that the balance of the hardships is in the patentee's favor, and that the public interest is not harmed if the court grants the injunction.  The District Court found in Myriad's favor on only one of these grounds, that of irreparable harm.  This finding was based on expert testimony from Myriad's damages expert, whose testimony the Court credited with regard to the effects on market entry by Ambry (and others) on determining the amount of damages owed should Myriad prevail, particularly with regard to the likelihood that Myriad would be undercompensated in view of the "complex pricing and sales factors in the case."  The Court also cited the unlikelihood that Myriad would be able to reverse the price erosion expected to occur with market entry of Ambry and other competitors.

    Ambry GeneticsThe rest of the prongs of the test were in Ambry's favor according to the District Court's opinion.  With regard to the balance of the hardships, the Court was not persuaded by Ambry's argument that its loss of its "head start" offset any harm to Myriad's franchise, the Court stating that "[the fact t]hat Myriad is a large company and can survive an injunction does not compel the Court to conclude that Defendant's loss of a head start outweighs Plaintiffs' loss of return on its years of work and substantial investment commercializing BRCA testing."  The Court was persuaded the argument that Ambry might go out of business if the injunction should be imposed, rejecting as inapposite cases from the Federal Circuit discounting this risk to the defendant.  "Notwithstanding the court's conclusion that Plaintiffs will suffer irreparable harm without an injunction," the District Court found that the balance of the hardships tilted in favor of Ambry, which could lose its business against the harm to Myriad, which is merely economic for a company "has enjoyed an exclusive monopoly in the BRCA1 and BRCA2 testing market for nearly two decades, and its own financial forecasts show that it expects to see increased revenue growth this year."  The Court further stated that "[e]ven without an injunction, Plaintiffs will undoubtedly continue to benefit from Myriad's expertise, market strength, and brand name recognition" as reasons supporting its finding that the hardships balanced in Ambry's favor.

    As for the public interest, the District Court stated that "both sides make compelling arguments that the public interest favors them."  Accordingly, the Court found that neither side "has shown that the public interest mandates either the imposition or denial of Plaintiffs' requested injunction."

    The most significant portion of the opinion is the District Court's finding that Myriad had not only failed to show a likelihood of success on the merits but that Ambry had introduced sufficient evidence to convince the Court that Myriad was unlikely to prevail and that the claims were invalid for reciting patent-ineligible subject matter.  Portions of the Court's opinion should come as no surprise:  the Court found that the primer and probe claims asserted by Myriad and argued to be patent-eligible subject matter because they were synthetic were not patent-eligible because they had the same sequence found in genomic DNA (a truer reading of the Supreme Court's AMP v. Myriad Genetics opinion than Myriad's interpretation of that opinion).  More troubling is the District Court's determination that the asserted method claims are also patent-ineligible, relying in large part on the reasoning by Judge Illson of the Northern District of California in Ariosa Diagnostics v. Sequenom, Inc. (currently in the briefing stage before the Federal Circuit).  That exercise in patent illogic has been discussed earlier; that the Utah District Court finds this reasoning persuasive is unhappy news for Myriad (as well as many other genetic diagnostic companies).

    There is one other interesting quotation from the District Court's opinion that deserves comment; according to the Court:

    The practical result of Myriad's patents has been to hinder or halt follow-up research, data sharing, patient testing, and the creation of additional and more affordable technologies for BRCA1 and BRCA2 testing.  For example, since about 2005, Myriad has declined to publicly share critical information regarding its classification of variants, including with its own patients.  Instead, Myriad retains that information in a private database.

    In so doing, Myriad distorts rather than serves the patent system's goal of public disclosure in exchange for exclusive rights.  In this way, Myriad has chosen a commercial path that turns much of our patent system policy on its head.

    Once again, Myriad's competitors have stolen the march in the public relations arena, even with a Utah judge, who makes these statements while acknowledging elsewhere in the brief Myriad's efforts to provide testing for women who cannot afford it and to arrange insurance reimbursement for those having health insurance.  Perhaps Myriad invited this outcome by asking for a preliminary injunction, which with its considerations of the public interest invite "expert" witness statements supporting this negative view.  But it does raise the question (stated somewhat differently by a prominent biotech patent attorney), "Since when does a patentee lose the right to assert her patent just because she acts like a jerk."  Appearances have been a motivating factor and a persuasive influence throughout the Myriad saga, and it is about time that Myriad acts to counter the perception that the company, and its patents, have been a hindrance rather than a help in bringing BRCA testing, and the accompanying health, social and economic benefits to U.S. women.

    Hat tip to Joe Allen for pointing out the quoted portions of the brief.

  • By Michael Borella

    Supreme Court Building #1In a previous article, we discussed the background of this case, and provided an overview of the Petitioner Brief of patentee Alice Corp.  In this article, we continue by covering the brief of the Respondent, CLS Bank.

    The Supreme Court is scheduled to hear oral arguments for this case on March 31st.

    CLS Bank's Brief

    CLS began its trek through the dark forest of § 101 by setting the tone of the conversation.  It noted that Alice is a patent assertion entity, rather than a company that practices its inventions.  Perhaps CLS Bank intended to leverage recent critical remarks made by members of Congress, as well as President Obama, about such entities.  CLS Bank also suggested that Alice's patents were issued under a "permissive standard for patent-eligibility" that pre-dates the Court's recent Bilski v. Kappos and Mayo v. Prometheus cases.

    CLSMoving on, CLS Bank asserted that Bilski is controlling law for this dispute, and that Alice's claims should suffer the same fate as Bilski's.  CLS Bank drew parallels between the method claims of Alice and Bilski.  Both are disembodied processes drawn to ways of managing risk that were well known in systems of commerce.  Holding Alice's patent valid would, in CLS Bank's view, foreclose the use of basic building blocks of scientific and technologic work in a way that goes beyond the contribution provided by Alice.

    Along the way, CLS Bank rejected Alice's attempt to differentiate between abstract ideas drawn to a fundamental scientific or mathematical principle and disembodied concepts that underlie all inventions.  However, CLS Bank downplayed this point by briefly addressing it in a footnote, and later providing an indirect rebuttal.  Particularly, CLS Bank noted that Bilski, as well as post-Bilski guidelines from the U.S. Patent and Trademark Office (USPTO), both provide examples of abstract ideas that are non-mathematical, human actions.

    One of Alice's more interesting arguments was its attempt to explain why its patents were valid under § 101, whereas Bilski's were not.  In essence, Alice argued that one of Bilski's dependent claims demonstrated that the invention of the independent claims could be expressed as a simple mathematical formula, and thus Bilski's entire invention was an abstract mathematical concept.  CLS Bank disputed this reading, pointing out that the dependent claim "provided only one way of calculating certain inputs for the method of hedging described in independent claim 1."  CLS Bank further argued that Bilski's dependent claims were "were ineligible not because they included a formula, but because they added mere 'token' limitations to the abstract idea" of the independent claim.  Surprisingly, CLS Bank did not bring up the doctrine of claim differentiation, which may have also supported its position.

    Instead, CLS Bank asserted that "[m]athematical formulas neither secure nor preclude eligibility, for a mathematical formula may describe a law of nature, a scientific truth, or an abstract idea.  As courts have recognized, mathematics may also be used to describe steps of a statutory method or elements of a statutory apparatus."  Thus, CLS Bank argued, claims that do not directly invoke mathematics, such as Alice's claim, can be patent-ineligible as abstract ideas.

    CLS Bank then undertook what essentially was an extended prior art analysis to establish that the "inventive concept" of Alice's claims, as well as its additional features, have long been known in the fields of economics and accounting.  Along the way, CLS Bank contended that the concept of preemption that plays so strongly in Gottschalk v, Benson and Parker v. Flook does not require that a claim "foreclose every conceivable application of an abstract idea to be ineligible."  Instead, quoting Mayo, CLS Bank asserted that "the underlying functional concern here is a relative one: how much future innovation is foreclosed relative to the contribution of the inventor," and that a patent that "forecloses more future invention than the underlying discovery could reasonably justify impedes progress, rather than promotes it."  Nevertheless, neither Mayo nor CLS Bank proposed a workable, objective method for weighing the contribution of an inventor versus foreclosed future innovation.

    This expression of concern, as well as CLS Bank's unease regarding the "breathtaking sweep of the asserted claims" cuts to the heart of the matter — is it appropriate to consider whether a claim element is known when performing a § 101 analysis, or should such deliberations be reserved for those of §§ 102 and 103?  Diehr and 1952 patent statute coauthor Judge Rich would require the separation of these three inquiries.

    CLS Bank, however, waved its hands at Diehr, burying this issue in a footnote.  In its fleeting discussion of the holding of Diehr, CLS Bank wrote that that case actually "prohibits dissecting the claims into old and new elements and then ignoring claim elements upon determining that they are non-novel."  CLS Bank attempted to align Mayo and Diehr by contending that Mayo "focuses attention on all claim elements, asking whether individually or 'as a whole' they are sufficient to transform the nature of the claim."  CLS Bank went on to shrewdly characterize Alice's disagreement with Judge Lourie's plurality opinion as actually a disagreement "with Justice Breyer's opinion for nine Members of this Court" when applying Mayo and Diehr.

    With respect to Alice's system and media claims, CLS Bank took the position that the issue "is not whether computer is tangible, but whether . . . computer implementation adds enough to confer eligibility."  Cast in this light, adding general purpose computer hardware to an unpatentable abstract idea would have the practical effect of granting a patent that preempts a broad range of uses of the abstract idea itself.  In essence, the contribution of the system and media claims is no greater than the contribution of method claims with the same elements.  CLS Bank also noted that before the USPTO, Alice conceded that "its later-issued system and media claims were no different in terms of patentability from the method claims in the first-issued '479 patent."

    CLS wrapped up with a parade of horribles that would occur should the Court hold that Alice's patents were valid.  Particularly, CLS Bank believes that allowing patents such as Alice's to be asserted would impede innovation in the information economy, permit inventors to claim more than they are entitled to, and invigorate patent assertion entities.

    Analysis

    The elephant in the room for CLS Bank is that it never directly addresses the propriety of a prior art analysis under § 101.  While not perfect, the principle that "each and every element as set forth in the claim [must be] found . . . in a single prior art reference" for a claim to be anticipated, as well as the Graham v. John Deere obviousness framework, are both workable standards.  Adding a similar "inventive analysis" as part of § 101 would allow patent examiners and litigation defendants to bring alleged prior art in through the back door in order to invalidate claims.  The danger of ignoring Diehr in this regard is illustrated by CLS Bank's subjective and conclusory analysis of the so-called additional elements contributed by Alice's claims.  It is unlikely that the more traditionalist Justices would agree to such a disruption in the stare decisis of patent law.

    CLS Bank's strongest position is based on the high-level similarity of Alice's and Bilski's method claims, and the fact that the Court struck down Bilski's claims only four years ago.  The Court is unlikely to walk back Bilski so soon, or to engage in the logical contortions required to differentiate the claims of these two cases.  However, it may be too much to ask the Justices to preclude all claims to tangible computing hardware that invoke abstract ideas.

    CLS Bank also set forth the concern that the patent law is slanted towards those who contribute only ideas over those who actually build products and services.  However, this point is at odds with the bedrock principle that, in the United States, an inventor is one who conceives of an idea, not one who only reduces that idea to practice.  Further, the current computer and Internet technology boom that is coincident with a ramp up of patents in related areas seems to belie the notion that the incentive to develop products is destroyed by the grant of patents.

    As many commentators have noted, and as Judge Newman eloquently explained in the Federal Circuit en banc decision, many if not all of the problems that CLS Bank has with Alice's claims would be addressed by proper § 102 and § 103 review of the claims.  If Alice's claims are truly directed to accounting techniques that date back to antiquity, then they should be anticipated or obvious.  If Alice's claims are too broad, or if their scope outweighs the inventor's contribution, they can be invalidated under § 102 or § 103.  Reducing the role of  subject matter eligibility to focus on whether claims truly fit into one of the four statutory classes would slice through the Gordian Knot that § 101 has become, and only serve to simplify and clarify proceedings in the USPTO and lower courts.

  • By Michael Borella

    Supreme Court Building #2On December 6th, the Supreme Court granted certiorari to a case that presents the question of "[w]hether claims to computer-implemented inventions — including claims to systems and machines, processes, and items of manufacture — are directed to patent-eligible subject matter within the meaning of 35 U.S.C. § 101 as interpreted by this Court?"  Thus, for the third time in five years, the highest court will once again review the patent-eligibility of so-called software and business method patents.

    This case was likely destined the Supreme Court once the Federal Circuit released its six-opinion en banc decision this May, demonstrating a severe intra-circuit split.  Judge Lourie's concurrence read Justice Breyer's 2012 Mayo v. Prometheus opinion in view of former Justice Stevens' 1978 Parker v. Flook decision, the latter a case that some thought had been in part overturned by 1980's Diamond v. Diehr and 2010's Bilski v. Kappos.  In Mayo, however, Justice Breyer resurrected the "inventive concept" analysis of Flook, and its propensity to blur the lines between the inquiries of patent-eligible subject matter, anticipation, and obviousness.

    In applying this analysis in CLS Bank, Judge Lourie set forth a procedure for analyzing claims that incorporate abstract ideas.  Since then, it has been roundly criticized for failing to produce an objective, workable standard.  Chief Judge Rader wrote separately, taking an approach that attempted to apply the inventive concept analysis while keeping § 101 separate from considerations of prior art.  Other panel opinions took different methodologies, relying on procedural issues to tip the scales, or advocating a dramatic reduction in scope of the judicial exceptions to § 101.

    Regardless, the en banc panel did little to clarify the bounds of patent-eligible subject matter, and may have muddied the waters even further.  Therefore, it is not at all surprising that the Supreme Court has taken up this case.  Hopefully, the Justices will clarify whether prior art should be considered in a 35 U.S.C. § 101 analysis, whether such an analysis should be applied to claims as a whole or to claim elements on a piecemeal basis, and whether recitation of general-purpose computer hardware (either as a claim element or as the statutory type of the claim) makes a claim any less abstract.  Or, being the Supreme Court, it is within their purview to decide the case on much narrower grounds.

    Now that the case has been fully briefed, we can look to the parties for the positions that they will likely be taking during oral argument.

    Brief Overview of the Case

    In 2007, CLS Bank filed a declaratory judgment action against Alice, contending that, among other things, Alice's U.S. Patents Nos. 5,970,479, 6,912,510, and 7,149,720 were invalid under § 101.  Alice filed counterclaims alleging infringement of these three patents.  Later, Alice's U.S. Patent No. 7,725,375 was added to the action, and the parties respectively asserted invalidity and infringement contentions for this patent as well.

    All four patents are from the same family and "share substantially the same specification."  The Federal Circuit plurality described the claimed subject matter as:

    [A] computerized trading platform used for conducting financial transactions in which a third party settles obligations between a first and a second party so as to eliminate "counterparty" or "settlement" risk . . . .   Settlement risk refers to the risk to each party in an exchange that only one of the two parties will actually pay its obligation, leaving the paying party without its principal or the benefit of the counterparty's performance.  Alice's patents address that risk by relying on a trusted third party to ensure the exchange of either both parties' obligations or neither obligation.

    Between the four patents, method, computer-readable medium (CRM), and system claims were asserted.  The parties stipulated that all claims, including the method claims, require "a computer including at least a processor and memory" and electronic implementation.

    The District Court held that all asserted claims failed to meet the requirements of § 101, and thus were invalid.  Particularly, the District Court concluded that the method claims were directed to an unpatentable abstract idea, and that the CRM and system claims would similarly preempt all practical applications of this idea, despite those claims falling under a different statutory category.

    On appeal, a Federal Circuit panel reversed the District Court on all counts, holding that all claims, including the method claims, were patent eligible under § 101.  CLS Bank petitioned the full Federal Circuit for review, which was granted.  Sitting en banc, seven of the ten judges overruled the panel and affirmed the District Court's ruling regarding the method and CRM claims.   However, this majority did not agree on the rationale for their conclusion.  Further, five of the judges found that the system claims were unpatentable, while the other five concluded that these claims passed muster under § 101.  Additionally, eight of the judges indicated that the method, CRM, and system claims must rise or fall together.

    Alice's Brief

    After the en banc Federal Circuit decision, Alice found itself in a difficult position.  To obtain a favorable Supreme Court review, it has to thread the eye of a needle by arguing that the Federal Circuit has left the law in a state of disarray, without suggesting that this disarray stems from the Supreme Court's own 2012 Mayo ruling.  Also, Alice has to distinguish its method claims over those that the Court struck down in Bilski, despite a high-level similarity thereto.

    Alice CorporationAlice began its substantive analysis by noting that while the requirements of §§ 102, 103, and 112 must be met for a patent to be valid, subject matter eligibility was the solely the province of § 101.  Alice quoted Judge Rich, "[a]chieving the ultimate goal of a patent [requires] having the separate keys to open in succession the three doors of sections 101, 102, and 103."  Thus, Alice signaled early that it was going to lean on Diehr as the controlling precedent.

    In presenting its claims, Alice wisely chose a system claim, claim 26 of the '375 patent, to discuss first.  This claim explicitly recites a computer, coupled to a communications controller and data storage, which communicates with a separate device.  Clearly, this claim recites tangible, physical hardware.  Alice also presented claim 33 of the '479 patent as a representative method claim.  However, this method claim is disembodied, and does not explicitly recite any physical hardware.  Instead, Alice contended that "a person of skill in the art would understand the methods, as claimed, to require use of a computer."  As noted above, this was also stipulated to by both parties in the district court proceedings.  Alice also briefly discussed its CRM claims, noting that the media is what allows the claimed systems to use the claimed methods.

    In its review of the case so far, Alice took the opportunity to poke at Judge Lourie's plurality opinion.  For instance, Alice, pointed out that Judge Lourie "look[ed] past the claim language" when conducting his piecemeal inventive concept analysis, and re-emphasized that "claims must be considered as a whole."  This sets the stage for Alice's later attempts to drive a wedge between Justice Breyer's Mayo analysis and the approach of the Federal Circuit's plurality.

    Alice's substantive argument consists of three main parts: (i) defining the "abstract idea" exception to § 101 and contrasting it to patent-eligible disembodied concepts, (ii) reiterating that claims must be read as a whole, and (iii) asserting that, regardless of whether Alice's claims encompass abstract ideas, they are patent-eligible.

    Alice began its discussion of abstract ideas by noting that, unlike laws of nature and physical phenomena, the Court has never clearly defined what it means by that term.  However, in Alice's view, the Court has treated abstract ideas substantively the same as it has treated laws of nature.  Both are fundamental truths that reflect "relationship[s] that [have] always existed" and therefore are "part of the storehouse of knowledge of all men . . . free to all men and reserved exclusively to none."  In other words, abstract ideas were not created or invented by humans, and are instead fundamental aspects of the universe that belong in the public domain.

    Discovery of an abstract idea, such as "mathematical formulas and the like," in and of itself does not warrant a patent for the discoverer.  Instead, "[w]hen a patent claim recites such an abstract idea, it can be patented only if the claim includes other elements or steps that go beyond the fundamental truth itself, thus limiting the claimed invention to a specific application and preserving public access to the fundamental truth."  Claiming a use of an abstract idea in a particular field does not lift the claim to the level of being patent-eligible, as no one is entitled to foreclose others' use of this public domain knowledge.

    Alice painted a picture in which Gottschalk v. Benson and Flook were decided in order to avoid the preemption of an abstract idea.  In these cases, the claimed abstract ideas were both algorithms, rather and mathematical relationships, but still were considered laws of nature.  Moving on to Bilski, Alice couched that case's claims as also being an algorithmic abstract idea.  Particularly, Alice pointed to the Court's statement that Bilski's "[c]laim 4 puts the concept articulated in claim 1 into a simple mathematical formula."

    To contrast with abstract ideas, Alice introduced the notion of "disembodied concepts."  In Alice's assessment, a disembodied concept does not fall into any of the four statutory categories of § 101, and instead is a "pure mental conception."  All claimed inventions involve, in one way or another, disembodied concepts.  The language of the claim is what makes these concepts statutory.  Further, and important to Alice's argument, a disembodied concept need not be an abstract idea or a law of nature, and therefore it is inappropriate to conduct a preemption analysis on such a claim.  Therefore, Judge Lourie's approach of asking whether such an "inventive [disembodied] concept" is wrapped up in a claim will always be answered in the affirmative, rendering his analysis to be excessively restrictive.

    Alice moved on to a related topic, that all claims, whether reciting an abstract idea or not, must be read as a whole.  Alice noted that the Court has found it "improper to look to the 'heart' or 'gist' of an invention, rather than the actual invention as described in the claim's language."  Instead, all of the claim's limitations and terms must be considered, because this language defined the boundaries that the "PTO has actually found deserving of a patent and what the public may not use."  Thus, as noted in Diehr, "[t]he 'novelty' of any element or steps in a process, or even of the process itself, is of no relevance in determining whether the subject matter of a claim falls within [§ 101]."

    In order to drive this point home, Alice needed to synthesize the seeming discrepancies between Diehr and Mayo.  In doing so, Alice noted that, like Flook, the claim under consideration in Mayo recited an algorithm for exploiting a law of nature, and that the claim covered all practical uses of this law of nature.  Thus, the "inventive concept" analysis of Mayo does not advocate dividing the claim into abstract and non-abstract elements, because in Mayo the claim was considered as a whole.  Thus, Alice purported that the Court in Mayo did not overrule Diehr, but instead "the 'inventive concept' inquiry asks whether additional steps in a claim that on its face recites a law of nature or fundamental truth do anything more than simply say 'apply it.'"

    From all this, Alice concluded that computer-implemented inventions are necessarily physical embodiments, and that such an invention that would "preempt use of a mathematical formula or other fundamental truth — as did the inventions in Benson and Flook — is ineligible for patenting."  However, computer-implemented inventions that do not exhibit such preemption are patent-eligible.

    Alice set forth a two-part test for determining the patent-eligibility of computer-implemented inventions:

    If the claim does not, on its face, recite a mathematical formula or other fundamental truth, it is eligible.

    [I]f the claim recites a particular application of a mathematical formula, such that others would not be foreclosed from using the formula in other practical applications, it is eligible.

    Alice reminded the Court that such a test is merely a threshold test for § 101 purposes.  Sections 102, 103, and 112 prevent patents from claiming inventions too broadly or without enough specificity.

    Finally, Alice argued that its claims were valid under § 101.  Alice noted that unlike Benson, Flook, and Bilski, Alice's claims had been allowed and issued by the U.S. Patent and Trademark Office.  Therefore, they enjoyed the presumption of validity, which saddled a high burden of proof on CLS Bank to establish otherwise.

    Alice first argued that its claims are not directed to an abstract idea because they do not recite a mathematical formula, or a fundamental truth that can be reduced to a mathematical formula.  Thus, by default, Alice's claims cannot preempt others' uses of abstract ideas.  Alice contended that Judge Lourie held otherwise because Alice's method claims were drawn to a disembodied concept, and that he failed to appreciate the difference between such a concept and an abstract idea.

    Alice also took issue with the lower court's "paraphrasing and dissecting the language of Alice's claims in its hunt for a disembodied concept, instead of reviewing the claims as a whole and as written."  Alice blamed this approach for "untethering" the claims from the recited real-world application.  Again, Alice emphasized that even their disembodied method claims were understood to require an unclaimed computer implementation, which Judge Lourie improperly ignored.

    In the alternative, Alice asserted that even if its claims encompassed an abstract idea, they are directed to the specific application of using a computer as the intermediary for third-party escrow transactions.  Alice pointed out that "a differently designed computer system could implement exchanges in other ways," and provided several examples thereof.  Thus, at worst, Alice's claims are similar to those of Diehr, where an abstract idea is invoked, but the claim as a whole does not preempt all uses of that idea in any particular field.

    Analysis

    Alice's main difficulty is that its method claims are similar in both structure and content to those of Bilski, and the Court may not believe that it is appropriate to hold that Alice's claims meet the § 101 requirements when Bilski's did not.  The Court might not defer to the stipulation that these disembodied method claims must be performed by a computer — the claims, on their face, could be performed between humans, perhaps with the assistance of pencil and paper.

    On the other hand, the Court should have a hard time concluding that Alice's system claims fail to pass muster under § 101, because doing so will put hundreds of thousands of similarly-claimed patented inventions at risk of being rendered invalid.  It is unlikely that the Court will want to stir the pot to such a degree without a clear signal from Congress that software and business methods should be frowned upon.

    Alice's abstract idea / disembodied concept dichotomy is a clever approach that could potentially be adopted by the Court in some form.  It appeals to logic, and frames the Court's previous decisions in a consistent fashion.  The wildcard is whether Alice's understanding of Mayo agrees with that of its author.  Justice Breyer might respond to Alice's interpretation by saying, "That's not what I meant."  Such a statement would throw the proverbial spanner in Alice's gears.

    Lastly, students of computer science — indeed anyone who has ever used a computer — might be entertained by Alice's seven-paragraph argument that a computer is a physical machine.  Alice has raised stating the obvious to a form of art.  Too bad that such an exercise is necessary in 2014.

  •         By Sherri Oslick

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Allergan, Inc. v. Actavis plc et al.
    2:14-cv-00188; filed March 6, 2014 in the Eastern District of Texas

    • Plaintiff:  Allergan, Inc.
    • Defendants:  Actavis plc; Actavis, Inc.; Watson Laboratories, Inc.; Actavis Pharma, Inc.

    Infringement of U.S. Patent No. 8,629,111 ("Methods of Providing Therapeutic Effects Using Cyclosporine Components," issued January 14, 2014) following a Paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Allergan's Retasis (cyclosporine ophthalmic emulsion, used to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca).  View the complaint here.


    Novartis Pharmaceuticals Corp. v. Pharmaceutics International, Inc.
    2:14-cv-01347; filed March 4, 2014 in the District Court of New Jersey

    Infringement of U.S. Patent No. 8,324,189 ("Use of Zolendronate for the Manufacture of a Medicament for the Treatment of Bone Metabolism Diseases," issued December 4, 2012) following a Paragraph IV certification as part of Pharmaceutics International's filing of an NDA (under § 505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version of Novartis' Zometa® (zoledronic acid, used for the prevention of skeletal-related complications associated with cancer).  View the complaint here.


    Amarin Pharmaceuticals Ireland Ltd. v. Omthera Pharmaceuticals Inc. et al.
    1:14-cv-00279; filed March 4, 2014 in the District Court of Delaware

    • Plaintiff:  Amarin Pharmaceuticals Ireland Ltd.
    • Defendants:  Omthera Pharmaceuticals Inc.; AstraZeneca Pharmaceuticals LP

    Infringement of U.S. Patent No. 8,663,662 ("Stable Pharmaceutical Compositions and Methods of Using Same" issued March 4, 2014) based on AstraZeneca's anticipated marketing and sale of their Epanova™ (mixture of polyunsaturated free fatty acids derived from fish oils for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia).  View the complaint here.

    Roxane Laboratories, Inc. v. Camber Pharmaceuticals, Inc. et al.
    2:14-cv-00232; filed March 4, 2014 in the Southern District of Ohio

    • Plaintiff:  Roxane Laboratories, Inc.
    • Defendants:  Camber Pharmaceuticals, Inc.; Invagen Pharmaceuticals, Inc.

    Infringement of U.S. Patent No. 8,563,032 ("Formulation and Manufacturing Process for Calcium Acetate Capsules," issued October 22, 2013) based on defendants' anticipated manufacture and sale of a generic calcium acetate capsule, having filed an ANDA to manufacture a generic version of Fresenius' PhosLo® Gelcaps (calcium acetate, used for the reduction of serum phosphorous in patients with end stage renal disease).  View the complaint here.

    Bausch & Lomb Inc. et al. v. Sandoz Inc. et al.
    1:14-cv-01325; filed March 2, 2014 in the District Court of New Jersey

    • Plaintiffs:  Bausch & Lomb Inc.; Bausch & Lomb Pharma Holdings Corp.; Mitsubishi Tanabe Pharma Corp.; Ube Industries, Ltd.
    • Defendants:  Sandoz Inc.; Sandoz International GmbH

    Infringement of U.S. Patent No. 6,780,877 ("Acid Addition Salt of Optically Active Piperidine Compound and Process for Preparing the Same," issued August 24, 2004) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Bausch & Lomb's Bepreve® (bepotastine besilate ophthalmic solution, used for the treatment of itching associated with allergic conjunctivitis).  View the complaint here.

  • CalendarMarch 12-13, 2014 – FDA Boot Camp*** (American Conference Institute) – New York, NY

    March 13, 2014 – "Patent Term Adjustments and Extensions: Leveraging Exelixis, Novartis, Other Decisions, and USPTO Rule Changes" (Strafford) – 1:00 to 2:30 pm (EST)

    March 13, 2014 – "Inter Partes Review: Nuts & Bolts" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    March 13, 2014 – "Understanding the New USPTO Final and Proposed Rules on PLT and the Hague Agreement" (West LegalEdcenter) – 12:00 to 1:00 pm (EDT)

    March 20, 2014 – "Parallel Patent Proceedings Before the PTAB and Federal Court Post-AIA — Navigating Litigation Stays, Discovery and Settlements Concurrent with PTAB Review" (Strafford) – 1:00 to 2:30 pm (EST)

    March 24-26, 2014 – Medical Device Patents*** (American Conference Institute) – Chicago, IL

    March 25, 2014 – 24th Annual Conference on USPTO Law and Practice (PTO Day) (Intellectual Property Owners Association and U.S. Patent and Trademark Office) – Washington, DC

    March 25, 2014 – "Big Data Litigation in an Era of Big Data Privacy Concerns: Recent Developments in International Data Privacy Law and Their Impact on U.S. Litigation" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    March 26, 2014 – "Trade Secret vs. Patent Protection After AIA: Making the Choice — Understanding AIA's Impact on Trade Secrets, Evaluating the Protection Options, Weighing the Benefits and Risks" (Strafford) – 1:00 to 2:30 pm (EDT)

    March 26-27, 2014 – Biotech Patenting*** (C5) – Munich, Germany

    March 31 to April 2, 2014 - Life Sciences Collaborative Agreements and Acquisitions*** (American Conference Institute) - New York, NY

    April 23, 2014 – European biotech patent law update (D Young & Co) – 4:00 am, 7:00 am, and 12:00 pm (ET)

    April 23-25, 2014 – 2014 Spring Intellectual Property Counsels Committee (IPCC) Conference (Biotechnology Industry Organization) – Palm Springs, CA

    April 28-29, 2014 – Paragraph IV Disputes*** (American Conference Institute) – New York, NY

    August 13-15, 2014 – Advanced Patent Law Seminars (Chisum Patent Academy) - Seattle, WA

    August 18-20, 2014 – Advanced Patent Law Seminars (Chisum Patent Academy) - Seattle, WA

    ***Patent Docs is a media partner of this conference or CLE